ESMO ADVANCED COURSE PROGRAMME PANCREATIC CANCER: FROM STANDARD TREATMENT TO INDIVIDUALIZATION

Barcelona, Spain 25-26 November 2024

CO-CHAIRS

Thierry Conroy, France Sylvie Lorenzen, Germany **SPEAKERS**

Michel Ducreux, France
Anna Falanga, Italy
Angela Lamarca, Spain
Teresa Macarulla, Spain
Emmanuel Mitry, France
Cindy Neuzillet, France
Gerald Prager, Austria
Oliver Strobel, Austria
Jean-Luc Van Laethem, Belgium
Valérie Vilgrain, France

LEARNING OBJECTIVES

- To get an updated overview of current treatment standards in pancreatic cancer discussed interactively based on patient cases, study data and guideline recommendations
- To work through the most important issues in an interdisciplinary way, and to ask the question: what do I do in my daily practice on next Monday?
- To think outside the box what could be current and future individualized therapy strategies?
- To inform individual clinical decision-making through the recommendations from ESMO Clinical Practice Guidelines

Monday, 25 November 2024

09:00-09:10	Welcome and introduction
10'	Welcome and learning objectives introduction Thierry Conroy, FR and Sylvie Lorenzen, DE
09:10-10:35	Session 1 – Resectable pancreatic cancer Chairs: Michel Ducreux, FR and Sylvie Lorenzen, DE
20'	Imaging, work-up, staging, and how to assess resectability Valérie Vilgrain, FR
25'	Resection and pathology; prognostic factors Oliver Strobel, AT
20'	Lessons from adjuvant therapies Thierry Conroy, FR
20'	Q&A
10:35-11:05	Coffee break

11:05-12:15	Session 2 – Neoadjuvant and induction approaches Chairs: Emmanuel Mitry, FR and Oliver Strobel, AT
20'	Pancreatic cancer in the era of neoadjuvant treatment: Oncological perspective Sylvie Lorenzen, DE
15'	'Induction therapy' for borderline resectable pancreatic cancer Gerald Prager, AT
15'	Specific surgical questions after neoadjuvant or induction therapies Oliver Strobel, AT
20'	Q&A
12:15-13:15	Lunch
13:15-14:35	Session 3 – Metastatic pancreatic cancer Chairs: Gerald Prager, AT and Jean-Luc Van Laethem, BE
20'	What are the best options as first line therapy? Michel Ducreux, FR
20'	What are the best options as second line therapy? Teresa Macarulla, ES
20'	What is the best sequence? Results of transcriptomic signatures Emmanuel Mitry, FR
20'	Q&A
14:35-15:05	Coffee break
15:05-16:45	Session 4 – Specific situations Chairs: Thierry Conroy, FR and Teresa Macarulla, ES
20'	Do personalized treatment approach by molecular profiling lead to better prognosis of metastatic pancreatic cancer? Angela Lamarca, ES
20'	Current treatment strategies for advanced pancreatic cancer in the elderly Jean-Luc Van Laethem, BE
20'	Venous thromboembolism in pancreatic cancer patients: ESMO Clinical Practice Guideline Anna Falanga, IT
20'	Interventions for improving palliative care and quality of life in pancreatic cancer Cindy Neuzillet, FR
20'	Q&A
19:00	Networking Dinner

Tuesday, 26 November 2024

09:00-12:30	Workshop sessions Three workshop sessions where clinical cases are presented by speakers with interactive questions and discussion with the audience (delegates will attend all 3 sessions on a rotation basis) 60' Workshop time
Workshop 1 60'	Current insights of chemotherapy for metastatic pancreatic cancer Michel Ducreux, FR and Gerald Prager, AT
Workshop 2 60'	How I treat locally advanced pancreatic cancer in 2024? Optimal treatment strategy? Sylvie Lorenzen, DE and Teresa Macarulla, ES
11:00-11:30	Coffee break
Workshop 3 60'	What is the next cutting-edge treatment for pancreatic cancer? Time for precision medicine? Angela Lamarca, ES
12:30-12:45	Feedback on the workshops Chairs: Angela Lamarca, ES, Teresa Macarulla, ES and Gerald Prager, AT
12:45-12:50	Conclusion and farewell Thierry Conroy, FR and Sylvie Lorenzen, DE
13:00-14:00	Lunch